Results 31 to 40 of about 88,666 (249)
Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia [PDF]
, 2000 At diagnosis, clonal gene rearrangement probes {[}retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3 ...
Braun, S. +5 more
core +1 more source
A case of myelogenous leucocytilemia [PDF]
Transactions of the Royal Academy of Medicine in Ireland, 1891 n ...
openaire +3 more sources
Chronic myeloid leukemia: past, present, future [PDF]
Einstein (São Paulo), 2011 The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann +1 more
doaj
European Journal of Translational Myology, 2021 Acute liver failure is a rare but catastrophic syndrome. Liver function tests usually reveal cholestatic or hepatocellular pattern, but in this case, we report a previously undescribed manifestation of this condition as isolated hyperbilirubinemia.
Nasrin Gholami +4 more
doaj +1 more source
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]
, 2016 CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno +10 more
core +2 more sources
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
Онкогематология, 2015 The article presents example of modeling for pharmacoeconomical-founded choice of chronic myelogenous leukemia treatment strategy related to therapeutic efficacy and economical rationality. The economic model of chronic myelogenous leukemia diagnosis and
V. A. Shuvaev +3 more
doaj +3 more sources
Haematologica, 2014 Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers ...
Husheng Ding +14 more
doaj +1 more source
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]
, 2011 The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin +30 more
core +2 more sources
Dasatinib: ten years of clinical practice worldwide
Онкогематология, 2016 The article contains results of meta-analysis of experience in use of second-generation tyrosine kinase inhibitors – dasatinib. The results of clinical trials dasatinib therapy in chronic myelogenous leukemia imatinib-resistant or intolerant patients are
K. M. Abdulkadyrov +2 more
doaj +1 more source
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]
, 2012 MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri +53 more
core +1 more source